Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EP 0057

Drug Profile

EP 0057

Alternative Names: EP-0057

Latest Information Update: 30 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ellipses Pharma
  • Developer Ellipses Pharma; National Cancer Institute (USA)
  • Class Antineoplastics; Camptothecins; Drug conjugates; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor-1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Ovarian cancer; Small cell lung cancer
  • Phase I/II Prostate cancer; Urogenital cancer

Most Recent Events

  • 12 Jun 2023 Ellipses Pharma withdrew a phase II trial due to utility analysis decision to terminate EP 0057 compound in Gastric cancer and Small-cell lung cancer in China, South Korea and Taiwan (NCT05411679)
  • 05 May 2023 Ellipses Pharma completes a phase II trial in Ovarian cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, Hungary and United Kingdome (IV) (NCT04669002)
  • 09 Jun 2022 Ellipses Pharma plans a phase II trial for Gastric cancer and Small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in China, South Korea and Taiwan (IV) in July 2022 (NCT05411679)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top